Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Lundbeck
|
| gptkbp:acquisitionYear |
2019
|
| gptkbp:focus |
monoclonal antibody therapeutics
|
| gptkbp:founded |
2004
|
| gptkbp:founder |
gptkb:Mark_Litton
Randall Schatzman Stephen M. Williams |
| gptkbp:headquarters_location |
gptkb:Bothell,_Washington,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alder BioPharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
Eptinezumab
|
| gptkbp:status |
defunct
|
| gptkbp:stockSymbol |
ALDR
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.alderbio.com/
|
| gptkbp:bfsParent |
gptkb:Clay_Siegall
|
| gptkbp:bfsLayer |
6
|